Phase 2Active, not recruiting
Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)
Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Retifanlimab (INCMGA00012) in Patients With Selected Sarcomas
- Sponsor
- Institut Bergonié (Academic or other)
- Enrolment
- 66 planned
- Conditions
- Resectable Sarcoma
- Interventions
- Doxorubicin; Ifosfamide; INCMGA00012
- Ages
- adults, older adults
- Registry
- NCT04968106, CTIS2023-509498-21-00, EUCTR2021-001085-37
Full record on ClinicalTrials.gov
From the registry
Multicenter, prospective, open-labeled, 2-arm, non-comparative randomized phase II trial to assess the antitumor activity of retifanlimab (INCMGA00012) in association with neoadjuvant chemotherapy
Primary outcomes
- Assessment of the antitumor activity of retifanlimab when prescribed in association with neoadjuvant chemotherapy (doxorubicin+ifosfamide)
History
Study completion expected
Last registry update
Primary completion
Started
Registered